Whereas targeted therapies are available for other breast cancer subtypes, including hormone receptor-positive and HER-2 amplified breast cancers, there aren’t any FDA-approved targeted therapies for TNBC, and treatment options are limited to chemotherapy that is usually ineffective especially in later stages. This evidence concerns the gene NR4A1 and breast cancer.